Drug Trial Radar · NCT02019706
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Feb 12, 2014
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Sponsor type
- NIH
- First posted
- Dec 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral source of ACTH cannot be found initially despite very detailed and extensive imaging, including studies such as computed tomography, magnetic resonance imaging, and octreotide scan (Octreoscan) using the standard dose of indium- 111 pentetreotide (\[111In-DTPA-D-Phe\]-pentetreotide). The sensitivity and specificity of structurally based imaging studies depends on anatomic alterations and the size of the tumor. In contrast, positron emission tomography (PET) and somatostatin ligand imaging detect pathologic tissue based on physiologic and biochemical processes within the abnormal tissue. This protocol tests the ability of \[18F\]-L-3,4-dihydroxyphenylalanine (18F-DOPA) PET, and the somatostatin imaging analogue, 68Ga-DOTATATE-PET, to localize the source of ectopic ACTH production.
Conditions
- ACTH
- Cushing's Syndrome
Interventions
DOTATATE PET-CTRadiation
68Ga-DOTATATE PET/CT
F-DOPA PET CTRadiation
68Ga-DOTATATE PET/CT
CT scanRadiation
routine CT scan
Routine MRI scanDiagnostic test
routine 1.5 or 3T MRI scan
Gated MRI scanDiagnostic test
Cardiac gated MRI scan
68Ga-DOTATATEDrug
68Ga-DOTATATE radioligand
18F-DOPADrug
18F-DOPA radioligand
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine which imaging technique (F-DOPA PET/CT, 68Ga-DOTATATE PET/CT, CT, and/or MRI) has the best sensitivity.Time frame: 6-12 months
- To determine if there is a combination of imaging tests with optimal diagnostic accuracy.Time frame: 6-12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.